Oncology

Real-world evidence shows Pluvicto matches pivotal trial benefits in PSMA-positive mCRPC, with longer PFS after an androgen receptor pathway inhibitor.

Enfortumab vedotin plus pembrolizumab boosts survival and pCR in muscle-invasive bladder cancer, according to EV-304 trial data.

Bhavana (Tina) Bhatnagar, DO, advocates for AI and diverse clinical trials to bridge equity gaps in precision oncology and value-based care.

Emerging CRC diagnostic tools along with better public awareness could help reverse rising deaths in younger adults, says Jordan Karlitz, MD.

The increase in CRC-related mortality in younger adults is driven by screening delays and advanced-stage diagnoses, according to Jordan Karlitz, MD.

A new study finds higher radiation to key brain stem cell regions in NSCLC brain metastases tied to shorter survival.

Many eligible patients miss lung cancer screening due to low awareness and systemic barriers, putting underserved groups at higher risk for late-stage disease.

Kathrin Dvir, MD, MSc, concludes by highlighting the importance of outreach, education, and trusted messaging to improve breast cancer screening adherence.

Ameet Patel, MD, concludes by outlining strategies to overcome operational, financial, and payer challenges in delivering advanced multiple myeloma therapies.

Sora Ely, MD, emphasized that national lung cancer screening rates remain below 10%, underscoring the urgent need for greater awareness and uptake.

Kathrin Dvir, MD, MSc, discusses how biomarker-driven care, targeted therapies, and evolving sequencing are shaping modern breast cancer treatment.

To conclude his conversation with AJMC, Jordan Karlitz, MD, outlines clinical, behavioral, and policy strategies to reverse rising CRC deaths in adults aged under 50.

Ameet Patel, MD, explains how multiple myeloma treatment settings depend on safety, logistics, and patient needs.

Today's approval enables once-monthly SC amivantamab dosing for patients with EGFR-mutant NSCLC, reducing clinic visits without compromising efficacy or safety.

Kohei Shitara, MD, discusses CLDN18.2-guided therapy, nivolumab plus zolbetuximab, and toxicity management in advanced gastric and gastroesophageal cancers.

Jordan Karlitz, MD, highlights racial, ethnic, and socioeconomic disparities in rising CRC mortality rates among younger adults, driven by gaps in screening and awareness.

Individuals can use these 5 ways to minimize their cancer risk during National Cancer Prevention Month and beyond.

Jordan Karlitz, MD, explains the rise in CRC-related deaths in younger adults, stressing the need for earlier screening and symptom awareness.

The FDA approved Optune Pax, a first-of-its-kind portable device delivering tumor-treating fields for locally advanced pancreatic cancer treatment at home.

This study evaluates inclusion of National Comprehensive Cancer Network (NCCN) guideline recommended biomarkers for metastatic non–small cell lung cancer (NSCLC) in commercially available targeted next-generation sequencing (NGS) panels.

Susan Vadaparampil, PhD, MPH, explains that aligning clinical trials with community needs can improve enrollment diversity.

Ameet Patel, MD, discusses scaling CAR T-cell therapy and bispecific therapies to improve access and potentially cure multiple myeloma.

Medically integrated dispensing (MID) models help build patient trust in pharmacists, which can help improve adherence, explains Kenneth Komorny, PharmD, BCPS.

Patient navigators, community health workers, and/or peer advocates serve as trusted community resources for patients, Susan Vadaparampil, PhD, MPH, says.

MID in oncology also enhances treatment adherence and improves patient outcomes, according to Kenneth Komorny, PharmD, BCPS.